-$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter
Brokerages expect Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) to post earnings per share of ($0.22) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings per share of ($0.30) during the same quarter last year, which suggests a positive year-over-year growth rate of 26.7%. The company is expected to announce its next earnings results on Tuesday, November 14th.
According to Zacks, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($1.05). For the next year, analysts anticipate that the firm will post earnings of ($0.96) per share, with EPS estimates ranging from ($0.98) to ($0.93). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Bellerophon Therapeutics.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03.
Several research analysts have recently commented on BLPH shares. ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, July 11th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Bellerophon Therapeutics in a report on Wednesday, September 6th.
COPYRIGHT VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/13/0-22-eps-expected-for-bellerophon-therapeutics-inc-blph-this-quarter.html.
A number of large investors have recently added to or reduced their stakes in BLPH. Renaissance Technologies LLC lifted its holdings in Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 238,300 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Bellerophon Therapeutics during the 1st quarter worth approximately $125,000. Vanguard Group Inc. lifted its holdings in Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after purchasing an additional 211,111 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Bellerophon Therapeutics during the 2nd quarter worth approximately $1,316,000. 45.85% of the stock is owned by institutional investors and hedge funds.
Bellerophon Therapeutics (NASDAQ BLPH) opened at 1.11 on Wednesday. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.69. The stock’s 50 day moving average price is $1.18 and its 200-day moving average price is $1.33. The firm’s market capitalization is $39.42 million.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.